Welcome to the #BCIpodcast! In this episode, we have the privilege of hosting Prof. #AnilKoul, a prominent figure in global public health and infectious diseases discovery. With over 20 years of experience in drug discovery and scientific innovation, Prof. Koul's contributions have made a lasting impact on the field. Currently serving as the Vice President and Head of the Global Public Health and Infectious Diseases Discovery unit at J&J Pharmaceuticals, Prof. Koul has played a crucial role in the development of #Bedaquiline, a revolutionary drug for drug-resistant tuberculosis. Bedaquiline has received conditional approval in numerous countries and has positively impacted the lives of thousands of TB patients. Join us as we delve into Prof. Koul's remarkable journey, from his tenure as the Director of the Institute of Microbial Technology to his appointment as an adjunct Professor of Translation Research at the London School of Hygiene and Tropical Medicine. We'll explore his expertise in moving drugs from discovery to clinical development and his passion for driving public sector innovations in neglected diseases. With an extensive publication record in prestigious scientific journals and holding more than 25 international patents, Prof. Koul's insights are invaluable. Discover his perspective on the future of global public health, the challenges in the field, and the importance of bridging the gap between scientific innovation and neglected diseases. Don't miss this enlightening conversation with Prof. Anil Koul, where we explore the frontiers of drug discovery, infectious diseases, and global health. Tune in to gain valuable knowledge and inspiration from a true leader in the field. #BCIpodcast #GlobalHealth #InfectiousDiseases #DrugDiscovery #ScientificInnovation #Tuberculosis #PublicHealthLeader

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related